Observational study shows association of high miR-301a levels with poor prognosis and temozolomide resistance in glioblastoma.
Objective: To study the role of microRNA-301a (miR-301a) in glioma. Methods: Real-time quantitative RT-PCR (qRT-PCR) was carried out to detect the miR-301a expression in tissues. CCK-8 assay and cell viability assay were used to determine cell proliferation and temozolomide (TMZ) resistance. The association between mir-301a and BTG1 was confirmed by luciferase reporter assay as well as Western blot. Results: The miR-301a expression was raised in glioma significantly. Obvious interrelation was detected between high miR-301a expression level with high WHO grade. The 5-year overall survival (OS) rate was dramatically reduced in patients with high miR-301a expression. Besides, miR-301a was a prognostic variable for OS rate. Moreover, miR-301a overexpression promoted glioblastoma cell proliferation and TMZ resistance through regulating BTG1. Conclusions: High miR-301a expression in glioma is participated in glioblastoma cell proliferation as well as TMZ resistance, which may help for the prognosis and treatment for glioma.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: